澳股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

ALGORAE PHARMACEUTICALS LTD

0.008

0.000

成交量：141.36万

成交额：1.14万

市值：1,618.46万

市盈率：-5.24

高：0.009

开：0.008

低：0.008

收：0.008

52周最高：0.024

52周最低：0.008

股本：20.23亿

流通股本：10.47亿

量比：3.31

换手率：0.14%

股息：- -

股息率：- -

每股收益(TTM):-0.002

每股收益(LYR):-0.002

净资产收益率：-83.53%

总资产收益率：-41.93%

市净率：3.80

市盈率(LYR):-5.24

数据加载中...

总览公司新闻资讯公告

Algorae Pharmaceuticals 获任主权人工智能基础设施计划创始成员及启动合作伙伴

Algorae Pharmaceuticals与Torrent Pharmaceuticals就两种仿制药在澳新地区达成许可与供应协议

Algorae制药与Zydus Lifesciences就10款产品达成澳新市场授权协议

Algorae Pharmaceuticals与彼得·麦卡勒姆癌症中心合作开展第二个AI驱动的药物协同筛选项目

Algorae制药公司达成协议将在澳大利亚和新西兰推出两款心血管及代谢疾病仿制药

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/1AI.AU/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"1AI.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"1AI.AU\",,,,,undefined,":{"symbol":"1AI.AU","market":"AU","secType":"STK","nameCN":"ALGORAE PHARMACEUTICALS LTD","latestPrice":0.008,"timestamp":1791868260452,"preClose":0.008,"halted":0,"volume":1413612,"delay":0,"changeRate":0,"nameEN":"ALGORAE PHARMACEUTICALS LTD","floatShares":1046585658,"shares":2023070000,"eps":-0.001527,"marketStatus":"Post Close","change":0,"latestTime":"10-13 16:21:08 AEDT","open":0.008,"high":0.009,"low":0.008,"amount":11379,"amplitude":0.125,"askPrice":0.009,"askSize":3593559,"bidPrice":0.008,"bidSize":346250,"shortable":3,"etf":0,"ttmEps":-0.001527,"tradingStatus":3,"nextMarketStatus":{"tag":"开盘","tradingStatus":0,"beginTime":1791932400000},"marketStatusCode":15,"adr":0,"exchange":"ASX","adjPreClose":0.008,"openAndCloseTimeList":[[1791846000000,1791867600000]],"volumeRatio":3.312814,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"1AI.AU","preClose":0.008,"auctionPrice":0.008,"auctionVolume":646495,"auctionTime":1791867601311,"referencePrice":0.008,"referenceTime":1791868260452,"auction":3,"marketStatus":"盘后竞价","timestamp":1791867601311}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"1AI.AU\",,,,,undefined,":{"symbol":"1AI.AU","floatShares":1046585658,"roa":"-41.93%","roe":"-83.53%","lyrEps":-0.001527,"volumeRatio":3.312814,"shares":2023070000,"dividePrice":0,"high":0.009,"amplitude":0.125,"preClose":0.008,"low":0.008,"week52Low":0.008,"pbRate":"3.80","psRate":"208.38","week52High":0.024,"institutionHeld":0,"latestPrice":0.008,"committee":-0.82423,"eps":-0.001527,"divideRate":0,"volume":1413612,"delay":0,"ttmEps":-0.001527,"open":0.008,"prevYearClose":0.014,"prevWeekClose":0.008,"prevMonthClose":0.009,"prevQuarterClose":0.009,"fiveDayClose":0.009,"twentyDayClose":0.009,"sixtyDayClose":0.012,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/1AI.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"1AI.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"1AI.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1199286258","title":"Algorae Pharmaceuticals 获任主权人工智能基础设施计划创始成员及启动合作伙伴","url":"https://stock-news.laohu8.com/highlight/detail?id=1199286258","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199286258?lang=zh_cn&edition=fundamental","pubTime":"2026-06-29 07:04","pubTimestamp":1782687856,"startTime":"0","endTime":"0","summary":"Algorae Pharmaceuticals Ltd 已被指定为一项主权人工智能基础设施计划的创始参与方及启动合作伙伴。这一任命标志着该公司在人工智能与医疗健康交叉领域迈出了重要一步，旨在通过构建国家级的AI基础设施来推动创新。作为启动伙伴，Algorae Pharmaceuticals 将参与该计划的早期开发与实施，有望利用先进的人工智能技术加速其药物研发进程。此举不仅强化了公司在生物科技前沿的地位，也可能为其带来新的增长机遇和战略合作空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["1AI.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169432775","title":"Algorae Pharmaceuticals与Torrent Pharmaceuticals就两种仿制药在澳新地区达成许可与供应协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1169432775","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169432775?lang=zh_cn&edition=fundamental","pubTime":"2026-05-06 06:55","pubTimestamp":1778021715,"startTime":"0","endTime":"0","summary":"Algorae Pharmaceuticals Ltd宣布与Torrent Pharmaceuticals签署重要合作协议，双方将就两种仿制药分子在澳大利亚和新西兰地区开展许可与供应合作。该协议的签署标志着两家制药企业在澳新市场的战略布局取得实质性进展。通过此项合作，Torrent Pharmaceuticals将获得在澳新地区销售特定仿制药的授权，而Algorae Pharmaceuticals则负责相关产品的供应保障。此次合作涉及的两个仿制药分子将为澳新地区的患者提供更多治疗选择，同时也将增强Algorae Pharmaceuticals在该区域医药市场的影响力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","1AI.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113355794","title":"Algorae制药与Zydus Lifesciences就10款产品达成澳新市场授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1113355794","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113355794?lang=zh_cn&edition=fundamental","pubTime":"2026-04-28 06:39","pubTimestamp":1777329568,"startTime":"0","endTime":"0","summary":"Algorae制药有限公司宣布与印度制药巨头Zydus Lifesciences签署了一项重要合作协议，获得后者10款药品在澳大利亚和新西兰市场的独家经销权。\n此次合作涵盖的治疗领域包括心血管、糖尿病和中枢神经系统药物，将显著扩充Algorae在澳新地区的产品管线。协议约定Zydus将负责药品生产供应，而Algorae则主导当地市场注册申报和商业化推广。\n这项战略合作标志着Algorae正式进军品牌药分销领域，有望通过引入Zydus经过市场验证的成熟产品，快速提升公司在南太平洋地区的市场占有率。双方表示将共同推进这些药品在澳新医疗体系的准入进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["1AI.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116454163","title":"Algorae Pharmaceuticals与彼得·麦卡勒姆癌症中心合作开展第二个AI驱动的药物协同筛选项目","url":"https://stock-news.laohu8.com/highlight/detail?id=1116454163","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116454163?lang=zh_cn&edition=fundamental","pubTime":"2026-03-30 05:58","pubTimestamp":1774821492,"startTime":"0","endTime":"0","summary":"Algorae Pharmaceuticals Ltd (1AI.AU) 已宣布与彼得·麦卡勒姆癌症中心建立合作伙伴关系，共同启动其第二个利用人工智能技术的药物协同筛选项目。此次合作旨在通过先进的计算方法，探索和验证不同药物组合在癌症治疗中的协同效应，以期发现更有效的治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["1AI.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199700351","title":"Algorae制药公司达成协议 将在澳大利亚和新西兰推出两款心血管及代谢疾病仿制药","url":"https://stock-news.laohu8.com/highlight/detail?id=1199700351","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199700351?lang=zh_cn&edition=fundamental","pubTime":"2026-02-09 06:04","pubTimestamp":1770588254,"startTime":"0","endTime":"0","summary":"Algorae Pharmaceuticals Ltd宣布已签署一项重要合作协议，计划在澳大利亚与新西兰市场同步上市两款针对心血管疾病和代谢紊乱的通用名药物。\n此次战略布局将显著提升该公司在大洋洲医药市场的竞争力，通过提供高性价比的替代治疗方案，有望缓解当地患者长期用药的经济压力。两款药物的上市也将进一步完善Algorae在慢性病治疗领域的产品矩阵。\n业内人士分析，此次合作将加速仿制药在澳新地区的市场渗透，为Algorae拓展亚太区域业务奠定坚实基础。随着人口老龄化趋势加剧，心血管与代谢疾病药物市场需求持续增长，此举契合区域医疗健康产业的发展方向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["1AI.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}]}}